Company News-宜明昂科英文

2023-03-11

Phase II clinical trial of ImmuneOnco Biopharmaceuticals IMM0306 completes first subject enrollment for dosing

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the Phase II clinical trial of ImmuneOnco Biopharmaceuticals bispecific antibody-receptor re

2023-01-29

ImmuneOnco’s Phase Ib/IIa clinical study of IMM0306 combined with lenalidomide in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin’s lymphoma has been approved by NMPA

On January 29, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the phase Ib/IIa clinical study of the company's self-developed bispecif

2023-01-20

Phase II clinical trial of Immune Onco IMM01 combined with PD-1 monoclonal antibody for relapsed and refractory classical Hodgkin's lymphoma (R/RcHL) completes the first subject to be administered

On January 20, 2023, ImmuneOnco Biomedical Technology (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that the first domestic SIRPαFc fusion protein drug targeting human CD47

2023-01-18

Phase Ib/IIa clinical study of ImmuneOnco IMM01 combined with bortezomib and dexamethasone in the treatment of multiple myeloma has been approved by the National Medical Products Administration (NMPA)

On January 18, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the Phase Ib/IIa clinical study of the first domestic SIRPαFc fusion protein

2022-12-14

ImmuneOnco’s IMM2520 obtained approval of clinical research from the US FDA

On December 14, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the newly-developed bispecific antibody-receptor recombinant protein drug (project number: IMM2520), targeting CD47 and PD-L1, obtained clinical research approval from the US FDA.